Halder Jamal August 27th, 2023
Psychotropic Medications
Psychotropic Medications
Antipsychotics Antidepressants Mood Stabilizers Anxiolytics
D2 antagonists
symptoms
D2 & 5-HT2 antagonists
& symptoms
2 Groups
Antipsychotics
Typical (First-Generation):
Atypical (Second-Generation):
Antipsychotics
High Potency
• Haloperidol
• Pimozide
• Fluphenazine
• Perphenazine
• Trifluoperazine
Low Potency
• Thioridazine
• Chlorpromazine
• Aripiprazole
• Asenapine
• Clozapine
• Olanzapine
• Quetiapine
• Iloperidone
• Paliperidone
• Risperidone
• Lurasidone
• Ziprasidone
Typical (First-Generation): Atypical (Second-Generation):
• Psychosis:
- Schizophrenia spectrum disorders.
- Bipolar with psychosis, MDD with psychotic features.
- Clozapine for resistant cases or those with persistent suicidality.
- Delirium.
• Bipolar disorder (prevent relapse)
• Obsessive compulsive disorder
• Tourette syndrome
• Huntington disease
Indications
Antipsychotics
Dopamine
Extrapyramidal symptoms (Acute Dystonia, Akathisia, Parkinsonism, Tardive dyskinesia)
Hyper-prolactinemia, neuroleptic malignant syndrome.
Histamine Sedation, weight gain, diabetes.
Adrenergic Postural hypotension, dizziness, syncope.
Muscarinic
Dry mouth, blurred vision, urinary retention, constipation, tachycardia, hypertension,
memory & cognitive problems, diabetes
Serotonin Metabolic: increased appetite, weight gain, diabetes, dyslipidemia.
• High potency FGAs: more anti-Dopamine side effects
• Low potency FGAs: more anti-HαM side effects
• SGAs: more anti-Serotonin side effects
Adverse Effects
Antipsychotics
Psychotropic Medications
Antipsychotics Antidepressants Mood Stabilizers Anxiolytics
• SSRIs: Selective Serotonin Reuptake Inhibitors
• SNRIs: Serotonin Norepinephrine Reuptake Inhibitors
• TCAs: Tricyclic antidepressants
• MAOIs: Monoamine Oxidase Inhibitors
• Atypical antidepressants.
Antidepressants
5 Groups
Add MoAs
SSRIs: Fluoxetine, paroxetine, sertraline, citalopram, escitalopram.
Antidepressants
• Mood: MDD, Dysthymia, PMDD (1st line)
• Anxiety: GAD, Panic disorder, Social phobia, Agoraphobia.
• Eating disorders: bulimia, binge-eating disorder, pica.
• Others: OCD, PTSD, Premature ejaculation.
• GI distress, headache.
• Rebound effects: anxiety, insomnia, mania (if given to bipolar)
• Sexual dysfunction: anorgasmia, erectile / ejaculatory dysfunction,↓ libido
• SIADH
• Serotonin syndrome (if combined with others)
SNRIs: Venlafaxine, desvenlafaxine, duloxetine, milnacipran, levomilnacipran.
Antidepressants
• MDD, GAD (2nd line)
• Panic disorder, Social phobia, PTSD, OCD (Venlafaxine).
• Neuropathic pain (e.g diabetic neuropathy)
• Fibromyalgia (Duloxetine and milnacipran)
•Similar to SSRIs, but also stimulant effects from norepinephrine:
• Sweating
• Insomnia
• Dry mouth
• Constipation
•Increased HR & BP
TCAs: Amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, doxepin.
Antidepressants
• MDD
• OCD (clomipramine), nocturnal enuresis (imipramine).
• Neuropathic pain treatment, Migraine prophylaxis.
• Anti-HαM.
• Prolong QT interval.
• Serotonin syndrome (if combined with others).
• Overdose is fatal: Convulsions, Cardiotoxicity, Coma, respiratory depression
Treatment: NaHCO3 to prevent arrhythmias, bezos for convulsions
MAOI: Tranylcypromine, phenelzine, isocarboxazid, selegiline
Antidepressants
• Atypical depression.
• Parkinson disease (selegiline).
• Hypertensive crisis: most notably with ingestion of tyramine foods.
• : Contraindicated with other serotinergic agents,
If stopped MOAI, you need to wait 2 weeks before changing to another
agent or stopping dietary restrictions.
Serotonin Syndrome
A potentially life-threatening condition caused by serotonergic overactivity
due to overdose or concomitant use of serotonergic drugs
Serotonin Syndrome
Treatment:
• Benzodiazepines and supportive care.
• Cyproheptadine (serotonin antagonist) if no improvement.
• Autonomic dysfunctios: Hyperthermia, Diaphoresis, Tachycardia, HTN.
• Neuromuscular Activity: Hyperreflexia, Hypertonia, Clonus.
• Altered mental status: Delirium, Coma.
Atypicals antidepressants:
Antidepressants
• Bupropion: inhibits NE & DA reuptake, less risk of sexual dysfunction &
weight gain.
• Mirtazapine: α2 antagonist, lead to sedation (good for insomnia),
increased appetite, weight gain (good for underweight patients)
• Trazodone: primarily for insomnia.
• Vilazodone.
• Vortioxetine.
Psychotropic Medications
Antipsychotics Antidepressants Mood Stabilizers Anxiolytics
• Lithium (1st line in European guidelines)
• Valproate (1st line in American guidelines)
• Lamotrigine (esp for depressive episode)
• Carbamazepine
• Atypical antipsychotics
• These drugs are used to terminate the acute episodes of bipolar disorder
(mania, hypomania, depression) and to prevent relapse.
• Avoid prescribing antidepressants to patients with bipolar disorder before
initiating mood stabilizers, because antidepressants can precipitate a
manic episode.
Mood Stabilizers
Nausea, vomiting, Dizziness, Tremors, Acne, Mild hypercalcemia,
Nephrogenic diabetes insipidus, Thyroid dysfunction, Teratogenic.
Narrow therapeutic index for toxicity.
Tremor, GI distress, Rash, Joint pain, Weight loss or gain, Teratogenic
Blurry vision, GI distress, weight losses, Stevens Johnson syndrome
Dizziness, Dry mouth, Constipation, Diplopia, Ataxia,
Agranulocytosis, Aplastic anemia, SIADH, SJS.
Adverse effects:
Lithium
Valproate
Lamotrigine
Carbamazepine
Mood Stabilizers
Psychotropic Medications
Antipsychotics Antidepressants Mood Stabilizers Anxiolytics
Anxiolytics
• Beta blockers
• Antidepressants
• Antipsychotics
• Antiepileptics
• Benzodiazepines
• Buspirone
Anxiolytics
• Benzodiazepines
• Buspirone
• Short-acting (half-life 1-12 h): midazolam, triazolam
• Intermediate-acting (12-40 h): lorazepam, oxazepam, alprazolam
• Long-acting (> 40 h): diazepam, clonazepam, tetrazepam, chlordiazepoxide.
• Enhances GABAa effect (inhibitory).
• Causes sedation, tolerance, dependence, respiratory depression, amnesia.
• Partial 5-HT1A receptor agonist.
• Does not cause sedation, addiction, or tolerance.
Psychotropic Medications.pdf

Psychotropic Medications.pdf

  • 1.
    Halder Jamal August27th, 2023 Psychotropic Medications
  • 2.
  • 3.
    D2 antagonists symptoms D2 &5-HT2 antagonists & symptoms 2 Groups Antipsychotics Typical (First-Generation): Atypical (Second-Generation):
  • 4.
    Antipsychotics High Potency • Haloperidol •Pimozide • Fluphenazine • Perphenazine • Trifluoperazine Low Potency • Thioridazine • Chlorpromazine • Aripiprazole • Asenapine • Clozapine • Olanzapine • Quetiapine • Iloperidone • Paliperidone • Risperidone • Lurasidone • Ziprasidone Typical (First-Generation): Atypical (Second-Generation):
  • 5.
    • Psychosis: - Schizophreniaspectrum disorders. - Bipolar with psychosis, MDD with psychotic features. - Clozapine for resistant cases or those with persistent suicidality. - Delirium. • Bipolar disorder (prevent relapse) • Obsessive compulsive disorder • Tourette syndrome • Huntington disease Indications Antipsychotics
  • 6.
    Dopamine Extrapyramidal symptoms (AcuteDystonia, Akathisia, Parkinsonism, Tardive dyskinesia) Hyper-prolactinemia, neuroleptic malignant syndrome. Histamine Sedation, weight gain, diabetes. Adrenergic Postural hypotension, dizziness, syncope. Muscarinic Dry mouth, blurred vision, urinary retention, constipation, tachycardia, hypertension, memory & cognitive problems, diabetes Serotonin Metabolic: increased appetite, weight gain, diabetes, dyslipidemia. • High potency FGAs: more anti-Dopamine side effects • Low potency FGAs: more anti-HαM side effects • SGAs: more anti-Serotonin side effects Adverse Effects Antipsychotics
  • 7.
  • 8.
    • SSRIs: SelectiveSerotonin Reuptake Inhibitors • SNRIs: Serotonin Norepinephrine Reuptake Inhibitors • TCAs: Tricyclic antidepressants • MAOIs: Monoamine Oxidase Inhibitors • Atypical antidepressants. Antidepressants 5 Groups
  • 9.
  • 10.
    SSRIs: Fluoxetine, paroxetine,sertraline, citalopram, escitalopram. Antidepressants • Mood: MDD, Dysthymia, PMDD (1st line) • Anxiety: GAD, Panic disorder, Social phobia, Agoraphobia. • Eating disorders: bulimia, binge-eating disorder, pica. • Others: OCD, PTSD, Premature ejaculation. • GI distress, headache. • Rebound effects: anxiety, insomnia, mania (if given to bipolar) • Sexual dysfunction: anorgasmia, erectile / ejaculatory dysfunction,↓ libido • SIADH • Serotonin syndrome (if combined with others)
  • 11.
    SNRIs: Venlafaxine, desvenlafaxine,duloxetine, milnacipran, levomilnacipran. Antidepressants • MDD, GAD (2nd line) • Panic disorder, Social phobia, PTSD, OCD (Venlafaxine). • Neuropathic pain (e.g diabetic neuropathy) • Fibromyalgia (Duloxetine and milnacipran) •Similar to SSRIs, but also stimulant effects from norepinephrine: • Sweating • Insomnia • Dry mouth • Constipation •Increased HR & BP
  • 12.
    TCAs: Amitriptyline, nortriptyline,imipramine, desipramine, clomipramine, doxepin. Antidepressants • MDD • OCD (clomipramine), nocturnal enuresis (imipramine). • Neuropathic pain treatment, Migraine prophylaxis. • Anti-HαM. • Prolong QT interval. • Serotonin syndrome (if combined with others). • Overdose is fatal: Convulsions, Cardiotoxicity, Coma, respiratory depression Treatment: NaHCO3 to prevent arrhythmias, bezos for convulsions
  • 13.
    MAOI: Tranylcypromine, phenelzine,isocarboxazid, selegiline Antidepressants • Atypical depression. • Parkinson disease (selegiline). • Hypertensive crisis: most notably with ingestion of tyramine foods. • : Contraindicated with other serotinergic agents, If stopped MOAI, you need to wait 2 weeks before changing to another agent or stopping dietary restrictions. Serotonin Syndrome
  • 14.
    A potentially life-threateningcondition caused by serotonergic overactivity due to overdose or concomitant use of serotonergic drugs Serotonin Syndrome Treatment: • Benzodiazepines and supportive care. • Cyproheptadine (serotonin antagonist) if no improvement. • Autonomic dysfunctios: Hyperthermia, Diaphoresis, Tachycardia, HTN. • Neuromuscular Activity: Hyperreflexia, Hypertonia, Clonus. • Altered mental status: Delirium, Coma.
  • 15.
    Atypicals antidepressants: Antidepressants • Bupropion:inhibits NE & DA reuptake, less risk of sexual dysfunction & weight gain. • Mirtazapine: α2 antagonist, lead to sedation (good for insomnia), increased appetite, weight gain (good for underweight patients) • Trazodone: primarily for insomnia. • Vilazodone. • Vortioxetine.
  • 16.
  • 17.
    • Lithium (1stline in European guidelines) • Valproate (1st line in American guidelines) • Lamotrigine (esp for depressive episode) • Carbamazepine • Atypical antipsychotics • These drugs are used to terminate the acute episodes of bipolar disorder (mania, hypomania, depression) and to prevent relapse. • Avoid prescribing antidepressants to patients with bipolar disorder before initiating mood stabilizers, because antidepressants can precipitate a manic episode. Mood Stabilizers
  • 18.
    Nausea, vomiting, Dizziness,Tremors, Acne, Mild hypercalcemia, Nephrogenic diabetes insipidus, Thyroid dysfunction, Teratogenic. Narrow therapeutic index for toxicity. Tremor, GI distress, Rash, Joint pain, Weight loss or gain, Teratogenic Blurry vision, GI distress, weight losses, Stevens Johnson syndrome Dizziness, Dry mouth, Constipation, Diplopia, Ataxia, Agranulocytosis, Aplastic anemia, SIADH, SJS. Adverse effects: Lithium Valproate Lamotrigine Carbamazepine Mood Stabilizers
  • 19.
  • 20.
    Anxiolytics • Beta blockers •Antidepressants • Antipsychotics • Antiepileptics • Benzodiazepines • Buspirone
  • 21.
    Anxiolytics • Benzodiazepines • Buspirone •Short-acting (half-life 1-12 h): midazolam, triazolam • Intermediate-acting (12-40 h): lorazepam, oxazepam, alprazolam • Long-acting (> 40 h): diazepam, clonazepam, tetrazepam, chlordiazepoxide. • Enhances GABAa effect (inhibitory). • Causes sedation, tolerance, dependence, respiratory depression, amnesia. • Partial 5-HT1A receptor agonist. • Does not cause sedation, addiction, or tolerance.